Table 4 Promising formulations for the treatment of bacterial infections
From: Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines
Lipid(s) and sterol used | Bacteria or disease | Cell line/animal model used | Administration route | Promising liposome formulation | References |
|---|---|---|---|---|---|
PC/PG/Chol, PC/PG/Chol/Man-PE, PC/PS/Chol, PC/DMTAP/Chol | Meningitis | Monocyte-derived human DCs and murine bone marrow-derived DCs | N/A | PC/PG/Chol/Man-PE and PC/DMTAP/Chol | [94] |
PC/Chol/SA, PC/Chol/PA and PC/Chol | Diphteria toxin | BALB/c, C57BL/6 and ddY mice; P815, P13.1 and CD8OVA cells | Subcutaneous | PC/Chol/SA | [93] |
DOTAP and DOPC | Melioidosis | Neutrophils and splenocytes from BALB/c mice | Intramuscular | DOTAP | [2] |
DOPE/DOTAP | E. coli | Mouse embryonic fibroblasts (MEF) and RAW 264.7 macrophages | N/A | DOPE/DOTAP | [92] |
DDA/Chol/Man-C6-Chol and DDA/Chol | E. coli | DC 2.4 cells | N/A | DDA/Chol/Man-C6-Chol | [19] |